WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Whitehawk Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.01+0.12 (+4.15%)
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.80 (+36.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Whitehawk Therapeutics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$69.35M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$86.06M
TTM Q2 2026
Free cash flow
-$69.35M
TTM Q2 2026
EPS, diluted
-$0.33
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $249.49M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.36
- Dividend yield
- –
- Free cash flow yield
- -27.80%
Fundamentals
- Revenue
- $0
- Net income
- -$79.83M
- EPS, diluted
- -$0.33
- Free cash flow
- -$69.35M
- Book value per share
- $2.21
- Diluted shares
- 83M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$0-100.0% YoY
Gross profit
$0-100.0% YoY
Operating income
-$86.06M
Net income
-$79.83M
EPS, diluted
–
Free cash flow
-$69.35M
Reported periodTrailing twelve months